I have advice for every BOTA holderJust pretend the SP is $7.00...

I have advice for every BOTA holder

Just pretend the SP is $7.00 and hope for better days.

It's only a loss when you sell it and BOTA still have a great drug and program.

If LANI had failed stage 2 the yes sell this bastard. But read this from today's ann for hope.

The Company is developing laninamivir octanoate, a long-acting neuraminidase inhibitor, administered by inhalation via the TwinCaps(R) dry powder inhaler, for the treatment of influenza A and B under an Investigational New Drug (IND) in the United States. Laninamivir octanoate (Inavir(R)) has been successfully developed in Japan by the Company's partner, Daiichi-Sankyo, where it was approved for the treatment and prevention of influenza A and B in 2010 and 2013, respectively. Since its launch in 2010, Inavir(R) has become the leading antiviral used to treat influenza in Japan.

Since the initiation of the contract with BARDA in April 2011, the Company has advanced the development of laninamivir octanoate under its IND as follows:

completed three Phase 1 clinical trials (ADME, Safety and Pharmacokinetics in Chronic Asthma Patients, and TQT);
completed the targeted enrollment in its Phase 2 IGLOO trial on a timely-basis, the top-line results of which are anticipated in the third quarter of 2014;
initiated enrollment in a Phase 1/2 trial in pediatric patients;
successfully completed required improvements to the TwinCaps(R) dry powder inhaler; and
made significant advancements in the process development and manufacturing facets of the program, such that the installation of a commercial scale filling and finishing line for the manufacture of TwinCaps(R) inhaler for laninamivir octanoate can be initiated.
"Given the commercial success of Inavir(R) in Japan over the past several years, the status of the program and with top-line data from the Phase 2 IGLOO trial anticipated in a matter of months, we are somewhat perplexed by this decision," stated Russell H. Plumb